TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
05 2023
Historique:
received: 21 01 2022
revised: 28 12 2022
accepted: 14 01 2023
pmc-release: 01 05 2024
medline: 25 4 2023
pubmed: 11 2 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

Aberrant DNA methylation is frequent in colorectal cancer (CRC), but underlying mechanisms and pathologic consequences are poorly understood. We disrupted active DNA demethylation genes Tet1 and/or Tdg from Apc There were increased numbers of small intestinal adenomas in Apc Our findings reveal a novel epigenetic regulation, linked to the type of genomic instability, by which TET1/TDG-mediated DNA demethylation decreases methylation levels and inflammatory/interferon/immune responses. CIMP in CRC is triggered by an imbalance of methylating activities over demethylating activities. These mice represent a model of CIMP CRC.

Sections du résumé

BACKGROUND & AIMS
Aberrant DNA methylation is frequent in colorectal cancer (CRC), but underlying mechanisms and pathologic consequences are poorly understood.
METHODS
We disrupted active DNA demethylation genes Tet1 and/or Tdg from Apc
RESULTS
There were increased numbers of small intestinal adenomas in Apc
CONCLUSIONS
Our findings reveal a novel epigenetic regulation, linked to the type of genomic instability, by which TET1/TDG-mediated DNA demethylation decreases methylation levels and inflammatory/interferon/immune responses. CIMP in CRC is triggered by an imbalance of methylating activities over demethylating activities. These mice represent a model of CIMP CRC.

Identifiants

pubmed: 36764492
pii: S0016-5085(23)00112-9
doi: 10.1053/j.gastro.2023.01.039
pmc: PMC10586516
mid: NIHMS1932834
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
Mixed Function Oxygenases EC 1.-
Proto-Oncogene Proteins 0
TET1 protein, human EC 1.-
TET1 protein, mouse 0
Tdg protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

921-936.e1

Subventions

Organisme : NCI NIH HHS
ID : R21 CA191956
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM144131
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078412
Pays : United States
Organisme : NCI NIH HHS
ID : R29 CA078412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218133
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States

Informations de copyright

Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.

Références

Methods Mol Biol. 2016;1465:111-27
pubmed: 27581143
Cell Rep. 2016 Feb 16;14(6):1283-1292
pubmed: 26854228
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Nat Commun. 2015 Nov 26;6:10071
pubmed: 26607761
Clin Epigenetics. 2019 Dec 16;11(1):196
pubmed: 31842975
N Engl J Med. 2021 Mar 25;384(12):1168-1170
pubmed: 33761214
PLoS Genet. 2013;9(2):e1003250
pubmed: 23408899
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Mol Carcinog. 2005 Sep;44(1):31-41
pubmed: 15937958
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16933-16942
pubmed: 31371502
Nat Rev Cancer. 2011 Sep 23;11(10):726-34
pubmed: 21941284
Cancer Res. 2014 Apr 15;74(8):2193-2203
pubmed: 24590060
Nature. 2022 May;605(7908):160-165
pubmed: 35477756
Cancers (Basel). 2013 Jun 25;5(3):786-814
pubmed: 24202321
Nat Rev Cancer. 2004 Dec;4(12):988-93
pubmed: 15573120
Nature. 2011 Feb 17;470(7334):419-23
pubmed: 21278727
Adv Genet (Hoboken). 2020 Nov 27;2(1):e10033
pubmed: 36618446
J Clin Invest. 2014 Jan;124(1):24-9
pubmed: 24382386
Science. 2009 May 15;324(5929):929-30
pubmed: 19372393
Sci Rep. 2015 Nov 25;5:16923
pubmed: 26603754
Nat Rev Mol Cell Biol. 2013 Jun;14(6):341-56
pubmed: 23698584
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Biotechnol. 2013 Jan;31(1):46-53
pubmed: 23222703
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Oncogene. 2015 Aug 6;34(32):4168-76
pubmed: 25362856
Oncogene. 2019 May;38(19):3710-3728
pubmed: 30674989
Nat Commun. 2017 Sep 14;8(1):539
pubmed: 28912502
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Cancer Res. 2015 May 15;75(10):2120-30
pubmed: 25808873
Nat Rev Cancer. 2004 Feb;4(2):143-53
pubmed: 14732866
Cell Stem Cell. 2011 Aug 5;9(2):166-75
pubmed: 21816367
DNA Repair (Amst). 2016 Aug;44:92-102
pubmed: 27247237
EMBO Rep. 2017 May;18(5):781-796
pubmed: 28325772
Biochim Biophys Acta. 2012 Jan;1825(1):77-85
pubmed: 22056543
Nat Commun. 2021 Jun 8;12(1):3464
pubmed: 34103493
Nucleic Acids Res. 2014 Jun;42(11):6956-71
pubmed: 24875481
Cancer Prev Res (Phila). 2011 Jun;4(6):907-15
pubmed: 21383028
Cancer Cell. 2018 Apr 9;33(4):721-735.e8
pubmed: 29622466
Gastroenterology. 2012 Dec;143(6):1442-1460.e1
pubmed: 23000599
Genes Chromosomes Cancer. 2003 Dec;38(4):382-8
pubmed: 14566859
Gastroenterology. 2021 Feb;160(3):690-709
pubmed: 33279516
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Science. 2009 May 15;324(5929):930-5
pubmed: 19372391
Cell. 2011 Jul 8;146(1):67-79
pubmed: 21722948
Science. 1990 Jan 19;247(4940):322-4
pubmed: 2296722
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Cell. 2021 Dec 22;184(26):6262-6280.e26
pubmed: 34910928
Science. 1985 Apr 12;228(4696):187-90
pubmed: 2579435
J Virol. 2011 Mar;85(6):2599-610
pubmed: 21209118
Epigenomics. 2012 Aug;4(4):459-67
pubmed: 22920184
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Sep 23;8(52):89988-89997
pubmed: 29163805
Nat Commun. 2016 Mar 02;7:10806
pubmed: 26932196
DNA Repair (Amst). 2015 Aug;32:33-42
pubmed: 26021671
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Res. 2013 Oct 1;73(19):5858-68
pubmed: 23801749

Auteurs

Rossella Tricarico (R)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Jozef Madzo (J)

Coriell Institute for Medical Research, Camden, New Jersey.

Gabrielle Scher (G)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Maya Cohen (M)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Jaroslav Jelinek (J)

Coriell Institute for Medical Research, Camden, New Jersey.

Shinji Maegawa (S)

University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Rajeswari Nagarathinam (R)

Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Carly Scher (C)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Wen-Chi Chang (WC)

Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Emmanuelle Nicolas (E)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Michael Slifker (M)

Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Yan Zhou (Y)

Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Karthik Devarajan (K)

Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Kathy Q Cai (KQ)

Experimental Histopathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Tim Kwok (T)

Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Pamela Nakajima (P)

Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Jinfei Xu (J)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Pietro Mancuso (P)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Valentina Doneddu (V)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Luigi Bagella (L)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.

Riley Williams (R)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Siddharth Balachandran (S)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Nicholas Maskalenko (N)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Kerry Campbell (K)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Xueying Ma (X)

Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Israel Cañadas (I)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Julen Viana-Errasti (J)

Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.

Victor Moreno (V)

Oncology Data Analytics Program, Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Laura Valle (L)

Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.

Sergei Grivennikov (S)

Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

Iuliia Peshkova (I)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

Natalia Kurilenko (N)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

Aleksandra Mazitova (A)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

Ekaterina Koltsova (E)

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

Hayan Lee (H)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Martin Walsh (M)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Reuben Duttweiler (R)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Johnathan R Whetstine (JR)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Timothy J Yen (TJ)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Jean-Pierre Issa (JP)

Coriell Institute for Medical Research, Camden, New Jersey.

Alfonso Bellacosa (A)

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: Alfonso.Bellacosa@fccc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH